Arena Pharmaceuticals, Inc presented preclinical data for its recently announced investigational compound, APD418, a first-in-class calcium-independent myofilament derepressor (CMD), ß3 adrenergic receptor (AdrR) selective antagonist, at the American Heart Association Scientific Sessions 2018.
SAN DIEGO, Nov. 13, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented preclinical data for its recently announced investigational compound, APD418, a first-in-class calcium-independent myofilament derepressor (CMD), ß3 adrenergic receptor (AdrR) selective antagonist, at the American Heart Association Scientific Sessions 2018. APD418 is being developed to improve cardiac contractility with minimal effect on heart rate and blood pressure for decompensated heart failure (DHF).
“A significant unmet medical need exists in the treatment of decompensated heart failure, the most common hospital diagnosis for patients over the age of 65, which continues to increase with the aging population,” said Preston Klassen, MD, MHS, Executive Vice President, Research and Development and Chief Medical Officer of Arena. “We are pleased to present new preclinical data demonstrating the potential of our first-in-class compound, APD418, to improve therapeutic options by enhancing cardiac contractility while avoiding the serious adverse events commonly associated with the current standard of care.”
Presentation Details
Session Title: New Insights into Pharmacological Therapy of CHF
Title: APD418, A Selective Beta3-Adrenergic Receptor Antagonist Enhances Cardiac Positive Inotropic and Lusitropic Responses to Dobutamine in Conscious, Chronically-Instrumented Dogs with Pacing-Induced Heart Failure: Assessment by Pressure-Volume Analysis (Rapid Fire Oral)
Session Title: Kenneth D. Bloch Memorial Lecture
Title: Adverse Functional Significance of Cardiac Beta3-Adrenergic Receptor Activation on Left Ventricular Contractile Performance in Conscious, Chronically-Instrumented Dogs with Pacing-Induced Heart Failure (Oral)
About APD418
APD418 is a first-in-class calcium-independent myofilament derepressor (CMD) for decompensated heart failure (DHF). APD418 is a ß3 adrenergic receptor (AdrR) selective antagonist designed to improve cardiac contractility with minimal effect on heart rate and blood pressure. Inhibition of ß3 AdrR mediated myofilament repression may provide a unique cardiomyocyte-specific target to enhance cardiac contractile performance while avoiding adverse events associated with current inotrope therapies. Arena discovered and developed this investigational drug candidate internally.
APD418 is preclinical, investigational compound that is not approved for any use in any country.
About Arena Pharmaceuticals
Arena Pharmaceuticals is driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. Arena’s proprietary pipeline includes multiple potentially first- or best-in-class assets with broad clinical utility. Ralinepag (APD811) is being evaluated in a Phase 3 program for pulmonary arterial hypertension (PAH). Etrasimod (APD334), with potential utility in a broad range of immune and inflammatory conditions, is being evaluated with late-stage clinical programs in ulcerative colitis (UC) and Crohn’s disease, as well as progressing programs for primary biliary cholangitis and atopic dermatitis. Arena is also evaluating olorinab (APD371) with a Phase 2 program for gastrointestinal pain. Arena continues to assess other earlier research and development stage drug candidates, including APD418 for decompensated heart failure.
In addition, Arena has several collaborations including with Everest Medicines Limited (ralinepag and etrasimod in Greater China and select Asian countries), Axovant Sciences GmbH (nelotanserin - Phase 2), Boehringer Ingelheim International GmbH (undisclosed target - preclinical), Outpost Medicine, LLC (undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai Inc. (BELVIQ® - marketed product).
Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These forward-looking statements may be accompanied by words such as “in development for,” “being developed to,” “potential,” “designed to,” “may,” “driven to,” “potentially,” “potentially,” or words of similar meaning, or they may be identified by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include, without limitation, statements about the following: the opportunity, development and potential of APD418 and Arena’s other investigational drug candidates, including to be first- or best-in-class or transformative, improve therapeutic options and avoid serious adverse events; Arena’s drive; and the potential of Arena’s assets, programs, and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena’s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include: the timing and outcome of research, development and regulatory review is uncertain; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; nonclinical and clinical data are voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; we expect to need additional funds to advance all of our programs, and you and others may not agree with the manner we allocate our resources; clinical trials and other studies may not proceed at the time or in the manner expected or at all; enrolling patients in our ongoing and intended clinical trials is competitive and challenging; our drug candidates may not advance in development or be approved for marketing; unexpected or unfavorable new data; risks related to developing and commercializing drugs; risks related to relying on partners and other third parties; Arena’s and third parties’ intellectual property rights; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena’s forward-looking statements are disclosed in Arena’s filings with the Securities and Exchange Commission (SEC), including but not limited to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, which was filed with the SEC on November 8, 2018. These forward-looking statements represent Arena’s judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
Corporate Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content to download multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-presented-preclinical-data-for-apd418-in-development-for-treatment-of-decompensated-heart-failure-at-american-heart-association-scientific-sessions-300748702.html
SOURCE Arena Pharmaceuticals, Inc.
Company Codes: NASDAQ-NMS:ARNA
